Inhibition of bone resorption in vitro and prevention of ovariectomy-induced bone loss in vivo by flurbiprofen nitroxybutylester (HCT1026)

K. J. Armour, Robert Jurgen Van T Hof, K. E. Armour, A. C. Torbergsen, P. Del Soldato, S Ralston

    Research output: Contribution to journalArticle

    28 Citations (Scopus)

    Abstract

    Objective. Inhibitors of prostaglandin production, such as nonsteroidal antiinflammatory drugs (NSAIDs), and pharmacologic nitric oxide (NO) donors, such as organic nitrates, have been suggested to protect against bone loss in both humans and experimental animals. Recently, a new class of nitrosylated NSAID (known as NO-NSAIDs) has been developed, which combines the properties of a NO donor with those of a cyclooxygenase (COX) inhibitor. This study investigated the effects of one of these compounds, flurbiprofen nitroxybutylester (HCT1026), on bone metabolism in vitro and in vivo.

    Methods. The effects of HCT1026 on osteoclast formation and resorption were determined in vitro using cocultures of primary mouse osteoblasts and osteoclasts. The effect of HCT1026 in vivo was assessed using a mouse model of ovariectomy-induced bone loss.

    Results. HCT1026 was significantly more efficacious than the parent compound, flurbiprofen, at inhibiting osteoclast formation and bone resorption in vitro, and these effects could not be reproduced by combinations of flurbiprofen with a variety of NO donors. Studies in vivo showed that HCT1026 protected against ovariectomy-induced bone loss by inhibiting osteoclastic bone resorption, whereas flurbiprofen at similar concentrations was ineffective.

    Conclusion. These data indicate that HCT1026 is a potent inhibitor of bone resorption in vitro and protects against ovariectomy-induced bone loss in vivo by a novel mechanism that appears to be distinct from its NO donor properties and from its inhibitory effects on COX activity. We conclude that HCT1026 may be of clinical value in the prevention and treatment of inflammatory diseases such as rheumatoid arthritis, which are characterized by joint inflammation as well as periarticular and systemic bone loss.

    Original languageEnglish
    Pages (from-to)2185-2192
    Number of pages7
    JournalArthritis & Rheumatism
    Volume44
    Issue number9
    DOIs
    Publication statusPublished - 2001

    Keywords

    • OSTEOBLAST-LIKE CELLS
    • OXIDE SYNTHASE EXPRESSION
    • NITRIC-OXIDE
    • ULCEROGENIC PROPERTIES
    • RHEUMATOID-ARTHRITIS
    • DONOR NITROGLYCERIN
    • MINERAL DENSITY
    • IN-VITRO
    • OSTEOCLAST
    • INTERLEUKIN-1

    Cite this

    Inhibition of bone resorption in vitro and prevention of ovariectomy-induced bone loss in vivo by flurbiprofen nitroxybutylester (HCT1026). / Armour, K. J.; Van T Hof, Robert Jurgen; Armour, K. E.; Torbergsen, A. C.; Del Soldato, P.; Ralston, S.

    In: Arthritis & Rheumatism, Vol. 44, No. 9, 2001, p. 2185-2192.

    Research output: Contribution to journalArticle

    Armour, K. J. ; Van T Hof, Robert Jurgen ; Armour, K. E. ; Torbergsen, A. C. ; Del Soldato, P. ; Ralston, S. / Inhibition of bone resorption in vitro and prevention of ovariectomy-induced bone loss in vivo by flurbiprofen nitroxybutylester (HCT1026). In: Arthritis & Rheumatism. 2001 ; Vol. 44, No. 9. pp. 2185-2192.
    @article{5fa1b108ba1f411bb6cf425efdabbc55,
    title = "Inhibition of bone resorption in vitro and prevention of ovariectomy-induced bone loss in vivo by flurbiprofen nitroxybutylester (HCT1026)",
    abstract = "Objective. Inhibitors of prostaglandin production, such as nonsteroidal antiinflammatory drugs (NSAIDs), and pharmacologic nitric oxide (NO) donors, such as organic nitrates, have been suggested to protect against bone loss in both humans and experimental animals. Recently, a new class of nitrosylated NSAID (known as NO-NSAIDs) has been developed, which combines the properties of a NO donor with those of a cyclooxygenase (COX) inhibitor. This study investigated the effects of one of these compounds, flurbiprofen nitroxybutylester (HCT1026), on bone metabolism in vitro and in vivo.Methods. The effects of HCT1026 on osteoclast formation and resorption were determined in vitro using cocultures of primary mouse osteoblasts and osteoclasts. The effect of HCT1026 in vivo was assessed using a mouse model of ovariectomy-induced bone loss.Results. HCT1026 was significantly more efficacious than the parent compound, flurbiprofen, at inhibiting osteoclast formation and bone resorption in vitro, and these effects could not be reproduced by combinations of flurbiprofen with a variety of NO donors. Studies in vivo showed that HCT1026 protected against ovariectomy-induced bone loss by inhibiting osteoclastic bone resorption, whereas flurbiprofen at similar concentrations was ineffective.Conclusion. These data indicate that HCT1026 is a potent inhibitor of bone resorption in vitro and protects against ovariectomy-induced bone loss in vivo by a novel mechanism that appears to be distinct from its NO donor properties and from its inhibitory effects on COX activity. We conclude that HCT1026 may be of clinical value in the prevention and treatment of inflammatory diseases such as rheumatoid arthritis, which are characterized by joint inflammation as well as periarticular and systemic bone loss.",
    keywords = "OSTEOBLAST-LIKE CELLS, OXIDE SYNTHASE EXPRESSION, NITRIC-OXIDE, ULCEROGENIC PROPERTIES, RHEUMATOID-ARTHRITIS, DONOR NITROGLYCERIN, MINERAL DENSITY, IN-VITRO, OSTEOCLAST, INTERLEUKIN-1",
    author = "Armour, {K. J.} and {Van T Hof}, {Robert Jurgen} and Armour, {K. E.} and Torbergsen, {A. C.} and {Del Soldato}, P. and S Ralston",
    year = "2001",
    doi = "10.1002/1529-0131(200109)44:9<2185::AID-ART372>3.0.CO;2-3",
    language = "English",
    volume = "44",
    pages = "2185--2192",
    journal = "Arthritis & Rheumatism",
    issn = "0004-3591",
    publisher = "John Wiley and Sons Inc.",
    number = "9",

    }

    TY - JOUR

    T1 - Inhibition of bone resorption in vitro and prevention of ovariectomy-induced bone loss in vivo by flurbiprofen nitroxybutylester (HCT1026)

    AU - Armour, K. J.

    AU - Van T Hof, Robert Jurgen

    AU - Armour, K. E.

    AU - Torbergsen, A. C.

    AU - Del Soldato, P.

    AU - Ralston, S

    PY - 2001

    Y1 - 2001

    N2 - Objective. Inhibitors of prostaglandin production, such as nonsteroidal antiinflammatory drugs (NSAIDs), and pharmacologic nitric oxide (NO) donors, such as organic nitrates, have been suggested to protect against bone loss in both humans and experimental animals. Recently, a new class of nitrosylated NSAID (known as NO-NSAIDs) has been developed, which combines the properties of a NO donor with those of a cyclooxygenase (COX) inhibitor. This study investigated the effects of one of these compounds, flurbiprofen nitroxybutylester (HCT1026), on bone metabolism in vitro and in vivo.Methods. The effects of HCT1026 on osteoclast formation and resorption were determined in vitro using cocultures of primary mouse osteoblasts and osteoclasts. The effect of HCT1026 in vivo was assessed using a mouse model of ovariectomy-induced bone loss.Results. HCT1026 was significantly more efficacious than the parent compound, flurbiprofen, at inhibiting osteoclast formation and bone resorption in vitro, and these effects could not be reproduced by combinations of flurbiprofen with a variety of NO donors. Studies in vivo showed that HCT1026 protected against ovariectomy-induced bone loss by inhibiting osteoclastic bone resorption, whereas flurbiprofen at similar concentrations was ineffective.Conclusion. These data indicate that HCT1026 is a potent inhibitor of bone resorption in vitro and protects against ovariectomy-induced bone loss in vivo by a novel mechanism that appears to be distinct from its NO donor properties and from its inhibitory effects on COX activity. We conclude that HCT1026 may be of clinical value in the prevention and treatment of inflammatory diseases such as rheumatoid arthritis, which are characterized by joint inflammation as well as periarticular and systemic bone loss.

    AB - Objective. Inhibitors of prostaglandin production, such as nonsteroidal antiinflammatory drugs (NSAIDs), and pharmacologic nitric oxide (NO) donors, such as organic nitrates, have been suggested to protect against bone loss in both humans and experimental animals. Recently, a new class of nitrosylated NSAID (known as NO-NSAIDs) has been developed, which combines the properties of a NO donor with those of a cyclooxygenase (COX) inhibitor. This study investigated the effects of one of these compounds, flurbiprofen nitroxybutylester (HCT1026), on bone metabolism in vitro and in vivo.Methods. The effects of HCT1026 on osteoclast formation and resorption were determined in vitro using cocultures of primary mouse osteoblasts and osteoclasts. The effect of HCT1026 in vivo was assessed using a mouse model of ovariectomy-induced bone loss.Results. HCT1026 was significantly more efficacious than the parent compound, flurbiprofen, at inhibiting osteoclast formation and bone resorption in vitro, and these effects could not be reproduced by combinations of flurbiprofen with a variety of NO donors. Studies in vivo showed that HCT1026 protected against ovariectomy-induced bone loss by inhibiting osteoclastic bone resorption, whereas flurbiprofen at similar concentrations was ineffective.Conclusion. These data indicate that HCT1026 is a potent inhibitor of bone resorption in vitro and protects against ovariectomy-induced bone loss in vivo by a novel mechanism that appears to be distinct from its NO donor properties and from its inhibitory effects on COX activity. We conclude that HCT1026 may be of clinical value in the prevention and treatment of inflammatory diseases such as rheumatoid arthritis, which are characterized by joint inflammation as well as periarticular and systemic bone loss.

    KW - OSTEOBLAST-LIKE CELLS

    KW - OXIDE SYNTHASE EXPRESSION

    KW - NITRIC-OXIDE

    KW - ULCEROGENIC PROPERTIES

    KW - RHEUMATOID-ARTHRITIS

    KW - DONOR NITROGLYCERIN

    KW - MINERAL DENSITY

    KW - IN-VITRO

    KW - OSTEOCLAST

    KW - INTERLEUKIN-1

    U2 - 10.1002/1529-0131(200109)44:9<2185::AID-ART372>3.0.CO;2-3

    DO - 10.1002/1529-0131(200109)44:9<2185::AID-ART372>3.0.CO;2-3

    M3 - Article

    VL - 44

    SP - 2185

    EP - 2192

    JO - Arthritis & Rheumatism

    JF - Arthritis & Rheumatism

    SN - 0004-3591

    IS - 9

    ER -